NewTimeSpace News: Sino Biopharmaceutical announced on June 17 that Dr. Chen Lieping and Dr. Lu Bai have been appointed as Independent Non-executive Directors with effect upon the conclusion of the Company’s annual general meeting. Dr. Chen Lieping is also appointed as a member of the Audit Committee, Remuneration Committee and Nomination Committee, while Dr. Lu Bai is appointed as a member of the Audit Committee.
NewTimeSpace News: Sige New Energy announced on June 17 that Huang Xueqi has resigned as Board Secretary and Joint Company Secretary to focus on the role of Chief Financial Officer. Qin Xing has been appointed as Board Secretary and Joint Company Secretary, with a three-year exemption from strict compliance with Rules 3.28 and 8.17 of the Listing Rules granted by The Stock Exchange of Hong Kong Limited (HKEX).
NewTimeSpace News: ZTHC announced on June 17 that it has completed the placing exercise under the general mandate. A total of 150 million new shares were placed at HK$0.36 per share, generating net proceeds of around HK$53 million.
NewTimeSpace News: Shanghai Electric announced on June 17 that Wintech, its non-wholly-owned subsidiary, will acquire 100% equity interest in Anghua Automation via private agreement transfer with a total transaction value of approximately RMB204 million. The acquisition of the 58.02% stake held by controlling shareholder Electric Holdings at a consideration of around RMB119 million constitutes a connected transaction.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jun 17, 2026, CONTEL(01912.HK) saw a loss of 15.38% in its share price, closing at HKD 1.65. During the session, it reached an intraday high of HKD 1.92
NewTimeSpace News: Shanghai Henlius Biotech, Ltd. (02696.HK) announced on 17 June that the Phase I clinical trial application for self-developed HLX3902 Injection, a STEAP1xCD3xCD28 trispecific antibody, has been approved by NMPA for metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors. The product simultaneously targets STEAP1, CD3 and CD28 to boost T-cell anti-tumor activity, with promising anti-tumor efficacy and safety demonstrated in preclinical studies. No trispecific antibodies targeting the three above antigens have been launched globally to date. The Company cautions there is uncertainty over successful R&D and commercialization of HLX3902. The candidate also obtained Australian clinical trial notification clearance in May 2026.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jun 17, 2026, CNBM(03323.HK) saw a gain of 24.95% in its share price, closing at HKD 6.61. and touched an intraday low of HKD 5.21.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jun 17, 2026, ONEFORCE HLDGS(01933.HK) saw a loss of 40.26% in its share price, closing at HKD 0.23. During the session, it reached an intraday high of HKD 0.43 and touched an intraday low of HKD 0.22.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jun 17, 2026, KINGBOARD HLDG(00148.HK) saw a gain of 17.68% in its share price, closing at HKD 116.5. During the session, it reached an intraday high of HKD 120.5 and touched an intraday low of HKD 97.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jun 17, 2026, ITC PROPERTIES(00199.HK) saw a gain of 7.32% in its share price, closing at HKD 2.2. During the session, it reached an intraday high of HKD 2.25 and touched an intraday low of HKD 2.05.
NewTimeSpace (newtimespace.com) News, By the close of trading on Jun 17, 2026, REGENT PACIFIC(00575.HK) saw a gain of 78.95% in its share price, closing at HKD 1.02. During the session, it reached an intraday high of HKD 1.22 and touched an intraday low of HKD 0.7.
NewTimeSpace News: Shanghai Henlius Biotech, Ltd. (02696.HK) announced on 17 June that Hanbeiyou (pertuzumab injection) has passed GMP compliance inspection issued by Shanghai Municipal Drug Administration. The Songjiang manufacturing base is now qualified for domestic commercial production of the product. Independently developed pertuzumab biosimilar for HER2-positive breast cancer, Hanbeiyou has obtained marketing approvals in China, the US and EU. Domestic sales of pertuzumab products reached approximately RMB2.728 billion in 2025 per IQVIA CHPA data.
NewTimeSpace News: Shanghai Pharmaceuticals Holding Co.,Ltd (02607.HK) issued an announcement on 17 June that Mr. Zhao Yong was elected as the employee representative director of the Company’s 9th Board of Directors at the 3rd Joint Session of the 3rd Employee Representative Congress held on 16 June 2026. His term of office aligns with that of the 9th Board. Currently serving as the Company’s Deputy Party Secretary and Vice President, Mr. Zhao previously held posts including Deputy Director of Shanghai Municipal Health and Family Planning Commission. He holds no shares in the Company and receives no separate remuneration for his directorship role.
NewTimeSpace News: SSY Group Limited (02005.HK) announced on June 17 that the trustee purchased a total of 380,000 Company shares on the open market pursuant to the Restricted Share Award Scheme at an average consideration of HK$2.2124 per share, with total consideration of approximately HK$840,700 (excluding transaction fees). Following the acquisition, the trustee holds 7,680,000 shares, representing around 0.260% of total issued shares.
NewTimeSpace News: Dowell Service Group Co. Limited (02352.HK) announced on 17 June that Ms. Luo Shaoying has resigned as Co-Chief Executive Officer with immediate effect, while continuing to serve as Chairman of the Board and Executive Director. Mr. Duan Zekun is appointed Co-CEO effective the same date, with a three-year appointment term and an annual salary of RMB1.2 million. Mr. Duan previously served as General Manager of Human Resources Center at Dima Industry.
NewTimeSpace News: K.H. Group Holdings Limited (01557.HK) issued a positive profit forecast on 17 June. The Group is expected to record a net profit of no more than HK$142 million for the financial year ending 31 March 2026, compared with a net loss of approximately HK$58 million in the previous financial year. The turnaround is chiefly driven by around HK$162.297 million gain arising from the deconsolidation of its wholly-owned subsidiary K.H. Foundation Limited. Actual results may differ and shall be subject to the final announcement.
